|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| A61K 47/68 | |||
| A61P 35/00 |
| (11) | Number of the document | 3371223 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16810243.2 |
| Date of filing the European patent application | 2016-10-27 | |
| (97) | Date of publication of the European application | 2018-09-12 |
| (45) | Date of publication and mention of the grant of the patent | 2021-03-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2016/001791 |
| Date | 2016-10-27 |
| (87) | Number | WO 2017/076492 |
| Date | 2017-05-11 |
| (30) | Number | Date | Country code |
| 15192851 | 2015-11-03 | EP | |
| 16178010 | 2016-07-05 | EP |
| (72) |
DOERNER, Achim, DE
TOLEIKIS, Lars, DE
SOOD, Vanita, D., CA
SELLMANN, Carolin, DE
KNUEHL, Christine, DE
|
| (73) |
Merck Patent GmbH,
Frankfurter Strasse 250, 64293 Darmstadt,
DE
|
| (54) | BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF |
| BI-SPECIFIC ANTIBODIES FOR ENHANCED TUMOR SELECTIVITY AND INHIBITION AND USES THEREOF |